GlassScriptPhysician profile
Anne M Hirsch
NPI 1407916513
$4,173.56
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $589 · 2020: $643 · 2021: $936 · 2022: $831 · 2023: $654 · 2024: $520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,174.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $928.61 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Sanofi-Aventis U.S. LLC | $430.06 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $363.32 | 2021-2023 | Eliquis, Camzyos |
| Abbvie INC. | $273.51 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $251.16 | 2019-2022 | |
| Novo Nordisk INC | $206.32 | 2021-2023 | Rybelsus, Ozempic |
| Lilly USA, LLC | $199.39 | 2021-2023 | Mounjaro, Jardiance, Emgality |
| Pfizer INC. | $193.47 | 2020-2024 | |
| Allergan, INC. | $164.53 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $157.36 | 2022-2024 | Xifaxan, Trulance |
| Esperion Therapeutics, INC. | $137.02 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $112.78 | 2021-2023 | |
| Nevro Corp. | $92.40 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.52 | 2022-2024 | Jardiance |
| Lundbeck LLC | $75.17 | 2023-2024 | Rexulti |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $72.80 | 2019-2024 | Otezla, Repatha |
| Ultragenyx Pharmaceutical INC. | $68.75 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $60.20 | 2024 | Voquezna |
| Glaxosmithkline, LLC. | $55.40 | 2021-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Abbott Laboratories | $44.94 | 2022 | |
| Therapeuticsmd, INC. | $35.83 | 2020 | |
| Edwards Lifesciences Corporation | $29.06 | 2023 | Sapien 3 Ultra Resilia |
| Medtronic, INC. | $21.52 | 2024 | Venaseal |
| Novartis Pharmaceuticals Corporation | $16.85 | 2019 | |
| Azurity Pharmaceuticals, INC. | $16.69 | 2024 | Horizant |
| Biohaven Pharmaceutical Holding Company LTD. | $16.57 | 2022 | |
| Currax Pharmaceuticals LLC | $16.17 | 2022 | |
| Amarin Pharma, INC. | $16.00 | 2021 | |
| Linus Health, INC. | $14.15 | 2024 | Core Cognitive Evaluation |
| Lucid Diagnostics INC. | $14.05 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $11.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Hirsch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.